Literature DB >> 20132063

Enhancing adoptive immunotherapy of cancer.

Jennifer A Westwood1, Linda J Berry, Leanne Xj Wang, Connie Pm Duong, Hollie J Pegram, Phillip K Darcy, Michael H Kershaw.   

Abstract

IMPORTANCE OF THE FIELD: Conventional therapies, including surgery, chemotherapy and radiotherapy have contributed much to cancer treatment. However, these treatment modalities fail in a large proportion of patients, and there is a great need for effective alternate therapies. Adoptive immunotherapy can be effective against some cancers that have failed all other treatment options, even when disease burdens are massive. AREAS COVERED IN THIS REVIEW: This review gives a brief introduction of the historical origins of adoptive immunotherapy and then provides details of strategies for increasing the potency of cell transfer. Approaches for enhancing adoptive immunotherapy include: selecting the right type of cell; providing cytokine support; preconditioning patients and tuning the tumor microenvironment. The review also provides insights into the safety, feasibility and costs of this form of therapy. WHAT THE READER WILL GAIN: This article will give the reader an appreciation of the potential of adoptive immunotherapy, as well as an understanding of some limitations and current approaches for optimizing the effectiveness of this approach. TAKE HOME MESSAGE: With recent developments in knowledge of the interactions between the immune system and tumors, the field of adoptive immunotherapy is now poised to make dramatic contributions to cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132063     DOI: 10.1517/14712591003610622

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  7 in total

1.  Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

Authors:  Christian S Hinrichs; Zachary A Borman; Luca Gattinoni; Zhiya Yu; William R Burns; Jianping Huang; Christopher A Klebanoff; Laura A Johnson; Sid P Kerkar; Shicheng Yang; Pawel Muranski; Douglas C Palmer; Christopher D Scott; Richard A Morgan; Paul F Robbins; Steven A Rosenberg; Nicholas P Restifo
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

2.  Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.

Authors:  Christopher A Klebanoff; Luca Gattinoni; Douglas C Palmer; Pawel Muranski; Yun Ji; Christian S Hinrichs; Zachary A Borman; Sid P Kerkar; Christopher D Scott; Steven E Finkelstein; Steven A Rosenberg; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

Review 3.  Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.

Authors:  L A Marr; D E Gilham; J D M Campbell; A R Fraser
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

4.  Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model.

Authors:  Stacey L Fanning; Jenny Zilberberg; Johann Stein; Kristin Vazzana; Stephanie A Berger; Robert Korngold; Thea M Friedman
Journal:  J Immunol       Date:  2012-11-30       Impact factor: 5.422

Review 5.  Therapeutic vaccines for cancer: an overview of clinical trials.

Authors:  Ignacio Melero; Gustav Gaudernack; Winald Gerritsen; Christoph Huber; Giorgio Parmiani; Suzy Scholl; Nicholas Thatcher; John Wagstaff; Christoph Zielinski; Ian Faulkner; Håkan Mellstedt
Journal:  Nat Rev Clin Oncol       Date:  2014-07-08       Impact factor: 66.675

6.  Genetic control of mammalian T-cell proliferation with a synthetic RNA regulatory system - illusion or reality?

Authors:  Sang Kil Lee; George A Calin
Journal:  Genome Med       Date:  2010-10-15       Impact factor: 11.117

7.  Reciprocal complementation of the tumoricidal effects of radiation and natural killer cells.

Authors:  Kai-Lin Yang; Yu-Shan Wang; Chao-Chun Chang; Su-Chen Huang; Yi-Chun Huang; Mau-Shin Chi; Kwan-Hwa Chi
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.